6.
Glickman S, McHutchison J, Peterson E, Cairns C, Harrington R, Califf R
. Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009; 360(8):816-23.
DOI: 10.1056/NEJMsb0803929.
View
7.
Grinlinton M, McGuinness M, Christie M, Oldfield R, Ramsaroop R, Moss D
. Ethnic disparities in Phyllodes Tumour in Aotearoa New Zealand: a retrospective review. ANZ J Surg. 2022; 92(3):431-436.
DOI: 10.1111/ans.17453.
View
8.
Mirghani R, Sayi J, Aklillu E, Allqvist A, Jande M, Wennerholm A
. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics. 2006; 16(9):637-45.
DOI: 10.1097/01.fpc.0000230411.89973.1b.
View
9.
Cheng L, Chiang S, Tu H, Chang S, Wang T, Ko A
. Genomewide scan for gout in taiwanese aborigines reveals linkage to chromosome 4q25. Am J Hum Genet. 2004; 75(3):498-503.
PMC: 1182028.
DOI: 10.1086/423429.
View
10.
Hu Y, He J, Chen G, Wang D, Liu Z, Zhang C
. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta. 2005; 353(1-2):187-92.
DOI: 10.1016/j.cccn.2004.11.005.
View
11.
Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A
. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol. 2007; 21(4):419-26.
DOI: 10.1111/j.1472-8206.2007.00510.x.
View
12.
Strafella C, Caputo V, Termine A, Barati S, Gambardella S, Borgiani P
. Analysis of Genetic Variability among Populations Highlights a Possible Link with COVID-19-Related Neurological Complications. Genes (Basel). 2020; 11(7).
PMC: 7397291.
DOI: 10.3390/genes11070741.
View
13.
Adler G, Loniewska B, Parczewski M, Kordek A, Ciechanowicz A
. Frequency of common CYP3A5 gene variants in healthy Polish newborn infants. Pharmacol Rep. 2009; 61(5):947-51.
DOI: 10.1016/s1734-1140(09)70154-9.
View
14.
Sakaue M, Fuke Y, Katsuyama T, Kawabata M, Taniguchi H
. Austronesian-speaking people in Papua New Guinea have susceptibility to obesity and type 2 diabetes. Diabetes Care. 2003; 26(3):955-6.
DOI: 10.2337/diacare.26.3.955-a.
View
15.
Taber D, Gebregziabher M, Srinivas T, Chavin K, Baliga P, Egede L
. African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients. Pharmacotherapy. 2015; 35(6):569-77.
PMC: 4534305.
DOI: 10.1002/phar.1591.
View
16.
Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T
. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics. 2002; 12(4):331-4.
DOI: 10.1097/00008571-200206000-00009.
View
17.
Liu C, Li Y, Guan T, Lai Y, Shen Y, Zeyaweiding A
. ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus. Cardiovasc Diabetol. 2018; 17(1):127.
PMC: 6142339.
DOI: 10.1186/s12933-018-0771-3.
View
18.
Bains R, Kovacevic M, Plaster C, Tarekegn A, Bekele E, Bradman N
. Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa. BMC Genet. 2013; 14:34.
PMC: 3655848.
DOI: 10.1186/1471-2156-14-34.
View
19.
Chambers G, Edinur H
. Reconstruction of the Austronesian Diaspora in the Era of Genomics. Hum Biol. 2021; 92(4):247-263.
DOI: 10.13110/humanbiology.92.4.04.
View
20.
Gervasini G, Vizcaino S, Gasiba C, Carrillo J, Benitez J
. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations. Ther Drug Monit. 2005; 27(6):819-21.
DOI: 10.1097/01.ftd.0000186914.32038.a0.
View